Phaseline

Targets › FBIA

FBIA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout May 2027.

Open in Phaseline: the race on FBIA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Global Alliance for TB Drug Developmentpretomanid
Prodrug converted to active TB-killing compound; bioreductive nitroimidazole inhibitor of
FBIAPhase 2Tuberculosis, PulmonaryMay 2027

Conditions

Tuberculosis, Pulmonary (1)

Modalities

small molecule (1)

Companies

Global Alliance for TB Drug Development (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.